Search

The clinical trial landscape has changed significantly post-pandemic, and many industry experiences and strategies emerged at the Drug Information Association (DIA) 2022 Global Annual Meeting over the summer. In this [...]

Background: Recently, drug development companies have sought out patient feedback to improve overall drug development. However, characterization of the overall impact and return on engaging with patients have not been determined.Methods: The Drug Information Association (DIA), the Tufts Center for the Study of Drug Development (Tufts CSDD), and 17 other stakeholder organizations collaborated on a study to (1) quantify and define patient-centric initiatives (PCIs) utilized in clinical research and development and (2) to define evidence-based metrics and performance indicators that demonstrate return on engagement (ROE) of specific PCIs. We conducted a literature review, industry surveys, and in-depth interviews to determine and measure the impact of adopted PCIs.Results: We identified and defined 30 PCIs used to engage with patients. We analyzed 121 case studies and created a comprehensive list of metrics assessing overall return to the organization and to patients. Advocacy Group Support and Involvement, Conducting Patient Advisory Panels, and Focus Groups were examples of PCIs with the lowest cost and largest impact with respect to quality, speed, and impact on the patient relative to other PCIs.Conclusion: The results from the literature review and use cases provide drug development teams with evidence and insights to help facilitate the adoption of specific PCIs within their organization and to help select those initiatives that would provide the highest impact to patients and development organizations. It is also hoped that the biopharmaceutical industry will apply the standardized metrics in the toolkit to systematically assess the overall return on engagement.

The article discusses How Virtual reality will transform meetings amid Coronavirus pandemic. Topics include virtual conferences can never replicate face interactions and in-person networking and from the exhibition perspective, working from a virtual platform allows the use of Artificial Intelligence; exhibitors can better target and reach out to prospective clients for business development; and virtual platform allows for a significant amount of data and analysis to take place at one time.